Mechanism on angiotensin II influencing early recurrence of atrial fibrillation after radiofrequency ablation via LR-4/NF-kB pathway

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006367

Enrollment

Unknown

Registered

2015-05-04

Start date

2015-06-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

olmesartan:olmesartan

control:Nil

Eligibility

Sex/Gender

All

Age

60 Years to 75 Years

Inclusion criteria

Inclusion criteria: According to the ethics rules and diagnostic criteria on 2010 ESC guidelines for the management of AF, the selection of cases underwent catheter ablation were enrolled in our study. (The patient Baseline clinical characteristics were shown in table 1). Types of AF were defined according to ESC guidelines. All human studies require institutional review board approval. They were newly enrolled in this study, and none had a history of ablation.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had known acute or chronic inflammatory conditions (including infectious, autoimmune, or cancerous diseases), renal disease, a history of myocardial infarction, or heart failure.

Design outcomes

Primary

Measure	Time frame
TLR4, MyD88, NF-kB;	—

Countries

China

Contacts

Public ContactFang Hong

de_61@163.com+86 21 66111529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026